J Liver Cancer.  2017 Mar;17(1):88-93. 10.17998/jlc.17.1.88.

A Case of Achieving Complete Remission with Combination of Sorafenib and Tegafur in Patients with Hepatocellular Carcinoma with Progression of Disease after Sorafenib Therapy

Affiliations
  • 1Department of Internal Medicine, Dongnam Institute of Radiological & Medical Sciences, Busan, Korea. mongmani@daum.net
  • 2Department of Radiology, Dongnam Institute of Radiological & Medical Sciences, Busan, Korea.
  • 3Department of Radiation Oncology, Dongnam Institute of Radiological & Medical Sciences, Busan, Korea.

Abstract

Sorafenib is the only approved targeted agent as the first line systemic therapy for treatment of advanced hepatocellular carcinoma (HCC). However, the improvement of survival duration under 3 months is far from clinical satisfactory and most patients experience disease progression within 6 months after sorafenib therapy. Unfortunately, second line systemic therapy after treatment failure of sorafenib was not established and there were no clear guidelines for salvage treatment modalities. Recently, studies suggests that combination of sorafenib and single cytotoxic agent can be relatively effective and safe strategy that achieves promising rates of local and systemic control in advanced HCC patients. Based on above suggestions, we herein offer our experience of a case achieved complete remission by combination therapy of sorafenib and tegafur in the patient with progressed disease after sorafenib therapy.

Keyword

Sorafenib; Hepatocellular carcinoma; Refractory; Cytotoxic agent; Combination

MeSH Terms

Carcinoma, Hepatocellular*
Disease Progression
Humans
Salvage Therapy
Tegafur*
Treatment Failure
Tegafur
Full Text Links
  • JLC
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr